Familial Dysautonomia (Riley-Day Syndrome)

Familial Dysautonomia (Riley-Day Syndrome)

Introduction

Familial Dysautonomia (Riley Day Syndrome) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Familial Dysautonomia (FD), alsoRiley-Day syndrome known as *, is a rare autosomal recessive neurodegenerative disorder that primarily affects the autonomic and sensory nervous systems. It is caused by mutations in the IKBKAP gene (now called ELP1*) on chromosome 9q31-33[^1]. The disease is characterized by impaired development and function of sensory and autonomic [neurons](/entities/neurons), leading to widespread neurological deficits.

FD is predominantly found in individuals of Ashkenazi Jewish descent, with a carrier frequency of approximately 1 in 30 in this population. The disease affects both the peripheral nervous system and central nervous system, with progressive neurodegeneration of sensory and autonomic ganglia[^2].

Genetics and Molecular Basis

Gene Mutation

Familial dysautonomia is caused by a common founder mutation in the ELP1 (elongator complex subunit 1, previously known as IKBKAP) gene. Over 99% of patients carry a T→C transition at position 6 of the intron 20 donor splice site (IVS20+6T>C), which causes skipping of exon 20 during mRNA splicing. This results in reduced production of functional ELP1 protein[^3].

Familial Dysautonomia (Riley-Day Syndrome)

Introduction

Familial Dysautonomia (Riley Day Syndrome) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Familial Dysautonomia (FD), alsoRiley-Day syndrome known as *, is a rare autosomal recessive neurodegenerative disorder that primarily affects the autonomic and sensory nervous systems. It is caused by mutations in the IKBKAP gene (now called ELP1*) on chromosome 9q31-33[^1]. The disease is characterized by impaired development and function of sensory and autonomic [neurons](/entities/neurons), leading to widespread neurological deficits.

FD is predominantly found in individuals of Ashkenazi Jewish descent, with a carrier frequency of approximately 1 in 30 in this population. The disease affects both the peripheral nervous system and central nervous system, with progressive neurodegeneration of sensory and autonomic ganglia[^2].

Genetics and Molecular Basis

Gene Mutation

Familial dysautonomia is caused by a common founder mutation in the ELP1 (elongator complex subunit 1, previously known as IKBKAP) gene. Over 99% of patients carry a T→C transition at position 6 of the intron 20 donor splice site (IVS20+6T>C), which causes skipping of exon 20 during mRNA splicing. This results in reduced production of functional ELP1 protein[^3].

The ELP1 gene encodes a protein that is a component of the Elongator complex, which is involved in:

• tRNA modification (specifically wobble uridine modification)
• Transcriptional elongation
• Neuronal development and migration

Inheritance Pattern

FD follows an autosomal recessive inheritance pattern:

• Both parents must carry one copy of the mutated gene
• Each pregnancy has a 25% chance of affected offspring
• Approximately 1 in 3,600 Ashkenazi Jewish births is affected

Pathophysiology

Neurodegeneration

The primary pathological feature of FD is the progressive degeneration of sensory and autonomic neurons. This includes:

Cellular Mechanisms

The Elongator complex deficiency leads to:

• Impaired tRNA modification: Reduced wobble uridine modification affects translation efficiency
• Defective neuronal migration: During development, neurons fail to properly migrate to their destinations
• Increased [apoptosis](/mechanisms/apoptosis): Sensory and autonomic neurons undergo programmed cell death
• Axonal degeneration: Long axons are particularly affected

Clinical Features

Autonomic Manifestations

• Orthostatic hypotension: Severe drop in blood pressure upon standing
• Temperature dysregulation: Inability to sweat properly or regulate body temperature
• Gastrointestinal dysfunction: Severe gastroparesis, feeding difficulties, cyclic vomiting
• Reduced tear production: Alacrima (absent tears)
• Speech and swallowing difficulties: Dysphagia, aspiration risk

Sensory Deficits

• Loss of pain and temperature sensation: Particularly in the periphery
• Impaired proprioception: Difficulty with balance and coordination
• Taste disturbances: Absence of taste buds (fungiform papillae)
• Insensitivity to hypoxia: Reduced awareness of breathlessness

Neurological Signs

• Ataxia: Coordination difficulties
• Muscle weakness: Particularly in distal muscles
• Developmental delays: Motor and cognitive milestones may be delayed
• Seizures: Occur in approximately 10-15% of patients

Other Associated Features

• Kyphoscoliosis: Spinal curvature
• Clubfoot: Congenital talipes equinovarus
• Osteopenia: Low bone density
• Chronic kidney disease: Develops in many adults

Diagnosis

Clinical Criteria

Diagnosis is based on:

Diagnostic Tests

• Genetic testing: PCR-based detection of the common IVS20+6T>C mutation
• Somatic mutation analysis: Can identify tissue-specific mosaicism
• Nerve conduction studies: Show sensory neuropathy
• Autonomic function tests: Assess cardiovascular reflexes

Disease Course and Prognosis

Natural History

FD is a progressive neurodegenerative disorder with symptoms worsening over time:

• Infancy/Childhood: Feeding difficulties, developmental delays
• Adolescence: Increasing autonomic crises, orthostatic hypotension
• Adulthood: Progressive neurological decline, organ system complications

Life Expectancy

With modern management, many patients survive into adulthood. Major causes of mortality include:

• Sudden unexplained death (likely cardiac arrhythmia)
• Respiratory complications
• Renal failure

Quality of Life

Modern multidisciplinary care has significantly improved outcomes:

• Early intervention therapies
• Aggressive nutritional support
• Cardiac monitoring
• Physical and occupational therapy

Management and Treatment

Current Treatment Approaches

There is no cure for FD, but comprehensive supportive care improves quality of life:

Autonomic Management

• Fludrocortisone: For orthostatic hypotension
• Midodrine: Alpha-agonist for blood pressure support
• Pyridostigmine: May improve autonomic function
• IVIg: Some benefit in select patients

Symptomatic Treatment

• Gastrostomy tube: For severe feeding difficulties
• Respiratory support: As needed
• Seizure control: Anticonvulsant medications
• Orthopedic interventions: For scoliosis, clubfoot

Emerging Therapies

Research and Clinical Trials

Current Research Focus

• Gene therapy development: AAV-based delivery systems
• Understanding genotype-phenotype correlations: Why some patients have milder disease
• Biomarker development: For monitoring disease progression
• Elongator complex biology: Basic science to identify new targets

Clinical Trials

Patients and families can find current trials at:

• [ClinicalTrials.gov](https://clinicaltrials.gov) - Search "familial dysautonomia"
• [FD Foundation](https://www.familyds.org) - Research updates

Animal Models

Mouse Models

Several mouse models of FD have been developed:

• Conditional knockout models: Tissue-specific ELP1 deletion
• Humanized models: With patient-specific mutations

• [Genes Index](/genes)
• [Diseases Index](/diseases)
• [Mechanisms Index](/mechanisms)
• [Neurodegeneration](/diseases/neurodegeneration)
• [Autonomic Nervous System](/entities/autonomic-nervous-system)
• [--](/proteins/n--cadherin-protein)

Background

The study of Familial Dysautonomia (Riley Day Syndrome) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [AAV2-mediated intravitreal delivery of exon-specific U1 snRNA rescues optic neuropathy in familial dysautonomia.](https://pubmed.ncbi.nlm.nih.gov/41536810/) (2026 Mar 12) - Molecular therapy. Nucleic acids
• [Multiple System Atrophy Combined Outcome Assessment (MuSyCA): process, format, and validation plan.](https://pubmed.ncbi.nlm.nih.gov/41762390/) (2026 Feb 28) - Clinical autonomic research : official journal of the Clinical Autonomic Research Society
• [Establishing minimally clinically important differences for the orthostatic hypotension questionnaire (OHQ).](https://pubmed.ncbi.nlm.nih.gov/41134458/) (2026 Feb) - Clinical autonomic research : official journal of the Clinical Autonomic Research Society
• [ELP1 Gene Augmentation Restores Visual Function in a Mouse Model of Familial Dysautonomia.](https://pubmed.ncbi.nlm.nih.gov/41542655/) (2026 Jan 11) - bioRxiv : the preprint server for biology
• [Exploratory Analysis of ELP1 Expression in Whole Blood From Patients With Familial Dysautonomia.](https://pubmed.ncbi.nlm.nih.gov/41385477/) (2025 Dec 12) - Annals of clinical and translational neurology

References

[^3]: [Reference missing - citation needed]

[^2]: [Reference missing - citation needed]

[^1]: [Reference missing - citation needed] Page created: 2026-03-01. Last updated: 2026-03-01.